Alyssa’s Story

Alyssa Currence just graduated high school, like many people this time of year. But few teens have gone through the senior year Alyssa has. The doctor had last Fall reluctantly told Alyssa and her mom Carolyn that he thought Alyssa might have Hodgkin’s disease, otherwise known as Hodgkin’s lymphoma, a type of cancer that affects the lymphatic system. "I was brokenhearted to have to tell her … ‘I know what you expect your senior year to be, but it’s not going to be that way. Let’s replace your senior year with cancer treatment,’" the doctor recalled. "It was disappointing to have to tell her that on the first day of her senior year, not because I thought she wasn’t going to make it," he said. "I was just sad that she was going to have to go through it." Alyssa and Carolyn looked at one another with disbelief and confusion. Cancer? How could Alyssa have cancer?



Alyssa's treatment would include 12 chemo sessions, and with those came the side effects: lost hair, nausea and vomiting. Yet through it all, Alyssa kep studying and practicing for the school musical. Even cancer wouldn't get her down.



After a senior year filled with uncertainty and discomfort, Alyssa received her diploma, and now she's preparing for a new stage in life.



You can read the entire three-part story on Alyssa's journey written wonderfully by Jenny Jones in the Daily News-Record. Used with permission of Ms. Jones.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap